AU2016250188C1 - Antibody-mediated neutralization of Chikungunya virus - Google Patents

Antibody-mediated neutralization of Chikungunya virus Download PDF

Info

Publication number
AU2016250188C1
AU2016250188C1 AU2016250188A AU2016250188A AU2016250188C1 AU 2016250188 C1 AU2016250188 C1 AU 2016250188C1 AU 2016250188 A AU2016250188 A AU 2016250188A AU 2016250188 A AU2016250188 A AU 2016250188A AU 2016250188 C1 AU2016250188 C1 AU 2016250188C1
Authority
AU
Australia
Prior art keywords
antibody
seq
fragment
chikv
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016250188A
Other languages
English (en)
Other versions
AU2016250188B2 (en
AU2016250188A1 (en
Inventor
James E. Crowe
Terence DERMODY
Laurie SILVA
Scott A. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of AU2016250188A1 publication Critical patent/AU2016250188A1/en
Application granted granted Critical
Publication of AU2016250188B2 publication Critical patent/AU2016250188B2/en
Priority to AU2022202819A priority Critical patent/AU2022202819C1/en
Publication of AU2016250188C1 publication Critical patent/AU2016250188C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
AU2016250188A 2015-04-14 2016-04-14 Antibody-mediated neutralization of Chikungunya virus Active AU2016250188C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202819A AU2022202819C1 (en) 2015-04-14 2022-04-28 Antibody-mediated neutralization of Chikungunya virus

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562147354P 2015-04-14 2015-04-14
US62/147,354 2015-04-14
PCT/US2016/027466 WO2016168417A2 (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of chikungunya virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202819A Division AU2022202819C1 (en) 2015-04-14 2022-04-28 Antibody-mediated neutralization of Chikungunya virus

Publications (3)

Publication Number Publication Date
AU2016250188A1 AU2016250188A1 (en) 2017-11-02
AU2016250188B2 AU2016250188B2 (en) 2022-02-03
AU2016250188C1 true AU2016250188C1 (en) 2022-08-11

Family

ID=57126199

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016250188A Active AU2016250188C1 (en) 2015-04-14 2016-04-14 Antibody-mediated neutralization of Chikungunya virus
AU2022202819A Active AU2022202819C1 (en) 2015-04-14 2022-04-28 Antibody-mediated neutralization of Chikungunya virus

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202819A Active AU2022202819C1 (en) 2015-04-14 2022-04-28 Antibody-mediated neutralization of Chikungunya virus

Country Status (27)

Country Link
US (2) US10787503B2 (enExample)
EP (1) EP3283101A4 (enExample)
JP (3) JP6979875B2 (enExample)
KR (2) KR102736152B1 (enExample)
CN (2) CN107708726B (enExample)
AR (1) AR104264A1 (enExample)
AU (2) AU2016250188C1 (enExample)
CA (2) CA2982491C (enExample)
CL (1) CL2017002596A1 (enExample)
CO (1) CO2017010316A2 (enExample)
CR (2) CR20170518A (enExample)
DO (1) DOP2017000236A (enExample)
EA (1) EA037060B1 (enExample)
EC (1) ECSP17075750A (enExample)
HK (1) HK1246671A1 (enExample)
IL (2) IL290449B2 (enExample)
MA (1) MA41517A (enExample)
MX (2) MX2017013286A (enExample)
MY (1) MY191666A (enExample)
NZ (1) NZ736445A (enExample)
PE (2) PE20180171A1 (enExample)
PH (2) PH12021500048A1 (enExample)
SG (2) SG11201708152SA (enExample)
TN (1) TN2017000438A1 (enExample)
TW (2) TWI854285B (enExample)
UA (1) UA125206C2 (enExample)
WO (1) WO2016168417A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
KR102029394B1 (ko) * 2017-11-14 2019-10-07 재단법인 바이오나노헬스가드연구단 치쿤구니아 바이러스 감염 진단용 단일클론항체, 이를 생산하는 하이브리도마 및 이를 이용한 치쿤구니아 바이러스 감염 진단 방법
US11802146B2 (en) 2018-01-05 2023-10-31 Modernatx, Inc. Polynucleotides encoding anti-chikungunya virus antibodies
WO2019156758A2 (en) * 2018-01-05 2019-08-15 Vanderbilt University Antibody-mediated neutralization of chikungunya virus
JP6906207B2 (ja) * 2018-02-09 2021-07-21 国立大学法人大阪大学 チクングニアウイルス検出用免疫クロマト分析装置
JP7359390B2 (ja) * 2018-02-09 2023-10-11 国立大学法人大阪大学 チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途
WO2019236875A1 (en) * 2018-06-06 2019-12-12 Albert Einstein College Of Medicine, Inc. Antibodies or antibody-fragments thereof targeting alphaviruses, and compositions and methods comprising same
US20230065377A1 (en) * 2019-08-31 2023-03-02 Vanderbilt University Human antibodies to alphaviruses
KR102202082B1 (ko) * 2019-09-25 2021-01-11 충북대학교 산학협력단 치쿤군야 바이러스의 외피단백질 도메인 ⅱ에 대해 특이적으로 결합하는 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
WO2022101805A1 (en) * 2020-11-13 2022-05-19 Emergent Biosolutions Canada Inc. Hyperimmune globulins for treatment of chikungunya virus infections
CN118956771A (zh) * 2024-04-24 2024-11-15 华南农业大学 一种杂交瘤细胞株、基孔肯雅病毒单克隆抗体及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015010125A1 (en) * 2013-07-19 2015-01-22 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101516395B (zh) * 2006-09-01 2014-03-26 伯哈拉特生物技术国际有限公司 抗屈曲病毒感染的疫苗
CA2598966A1 (en) 2007-09-07 2009-03-07 Institut Pasteur Anti-chikungunya monoclonal antibodies and uses thereof
US9000131B2 (en) * 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
WO2011124635A1 (en) 2010-04-07 2011-10-13 Humalys Binding molecules against chikungunya virus and uses thereof
TW202300515A (zh) * 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015010125A1 (en) * 2013-07-19 2015-01-22 Integral Molecular, Inc. Antibodies against chikungunya virus and uses thereof

Also Published As

Publication number Publication date
KR102736152B1 (ko) 2024-11-28
JP6979875B2 (ja) 2021-12-15
DOP2017000236A (es) 2017-12-15
KR20230087616A (ko) 2023-06-16
US11345743B2 (en) 2022-05-31
US10787503B2 (en) 2020-09-29
CA2982491A1 (en) 2016-10-20
MY191666A (en) 2022-07-06
EP3283101A4 (en) 2019-01-16
AU2022202819C1 (en) 2025-04-03
CA3176525A1 (en) 2016-10-20
PE20180171A1 (es) 2018-01-22
JP2021144047A (ja) 2021-09-24
WO2016168417A3 (en) 2017-01-05
IL290449B1 (en) 2023-12-01
TWI772257B (zh) 2022-08-01
ECSP17075750A (es) 2018-02-28
CN114478756A (zh) 2022-05-13
AU2016250188B2 (en) 2022-02-03
PE20220297A1 (es) 2022-03-07
SG10202107295XA (en) 2021-08-30
US20180079802A1 (en) 2018-03-22
CR20170518A (es) 2018-01-25
CA2982491C (en) 2023-08-29
BR112017021952A2 (pt) 2018-07-10
UA125206C2 (uk) 2022-02-02
EA201792220A1 (ru) 2018-03-30
CN107708726B (zh) 2022-01-14
IL290449B2 (en) 2024-04-01
NZ736445A (en) 2023-06-30
CL2017002596A1 (es) 2018-05-18
TN2017000438A1 (en) 2019-04-12
TW201643189A (zh) 2016-12-16
IL254891B (en) 2022-03-01
TWI854285B (zh) 2024-09-01
WO2016168417A2 (en) 2016-10-20
TW202248210A (zh) 2022-12-16
MX2017013286A (es) 2018-06-19
PH12017501865A1 (en) 2018-03-05
KR102541905B1 (ko) 2023-06-12
US20200277359A1 (en) 2020-09-03
AU2016250188A1 (en) 2017-11-02
NZ775007A (en) 2024-08-30
AU2022202819A1 (en) 2022-05-19
AR104264A1 (es) 2017-07-05
CN114478756B (zh) 2024-08-23
KR20180004403A (ko) 2018-01-11
JP2022174144A (ja) 2022-11-22
JP2018520334A (ja) 2018-07-26
MX2021013207A (es) 2021-12-10
MA41517A (fr) 2017-12-19
HK1246671A1 (zh) 2018-09-14
SG11201708152SA (en) 2017-11-29
AU2022202819B2 (en) 2024-09-12
IL290449A (en) 2022-04-01
EA037060B1 (ru) 2021-02-01
CR20210438A (es) 2021-10-04
CO2017010316A2 (es) 2017-12-15
CN107708726A (zh) 2018-02-16
IL254891A0 (en) 2017-12-31
JP7536059B2 (ja) 2024-08-19
EP3283101A2 (en) 2018-02-21
PH12021500048A1 (en) 2022-05-11

Similar Documents

Publication Publication Date Title
US11345743B2 (en) Antibody-mediated neutralization of chikungunya virus
US11054423B2 (en) Antibody-mediated neutralization of ebolaviruses
US20230122364A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US11851478B2 (en) Antibody-mediated neutralization of chikungunya virus
HK40072444B (zh) 抗体介导的切昆贡亚热病毒的中和
HK40072444A (en) Antibody-mediated neutralization of chikungunya virus
US20230085393A1 (en) Human antibodies that neutralize zika virus and methods of use therefor
BR112017021952B1 (pt) Anticorpo monoclonal recombinante, seus usos, composição farmacêutica, métodos para produção do dito anticorpo bem como para detecção de uma infecção com vírus chikungunya em um indivíduo, e kit

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 12 APR 2022

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 12 APR 2022

FGA Letters patent sealed or granted (standard patent)